May 15, 2023 / 05:30PM GMT
Jon Wolleben - JMP Securities - Analyst
Good afternoon, everybody. My name is Jon Wolleben, Senior Analyst here at JMP Securities. Thanks for joining us for our afternoon session with Spruce Biosciences. We have CEO Javier Szwarcberg, to walk us through the story, where I do a little Q&A. But at first, Javier has some prepared remarks, so I will jump in after that. And if you have questions at the end, just feel free to raise your hand, and we'll answer as needed.
Javier Szwarcberg - Spruce Biosciences, Inc. - CEO
Terrific. Thank you, thank you for having me today. So good afternoon, everyone. My name is Javier Szwarcberg, as Jon said, I'm the CEO of Spruce. Spruce is a late-stage biopharma company focused on developing assets for rare endocrine diseases. Our main focus is in CAH. We think CAH provides a very large market opportunity, about $3 billion market as a whole.
Very large unmet need, low competitive pressure today, and with a disease that hasn't seen any type of innovation in at least 56 years since the advent of synthetic steroids.
Spruce Biosciences Inc at JMP Securities Life Sciences Conference Transcript
May 15, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers